Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a Rat model of parkinson's disease

Neuropsychopharmacology

Volumn 34, Issue 12, 2009, Pages 2477-2488

  Lindgren, Hanna S ^a   Ohlin, K Elisabet ^a   Cenci, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

6 OHDA; Angiogenesis; Blood brain barrier; Dopamine receptors; Dyskinesia; L DOPA

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; BENSERAZIDE; BIOLOGICAL MARKER; BROMOCRIPTINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; LEVODOPA; NESTIN; OXIDOPAMINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BASAL GANGLION; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; DYSKINESIA; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXPERIMENTAL MODEL; FEMALE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; LOW DRUG DOSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; UPREGULATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; AMINOACETONITRILE; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; BENZAZEPINES; BROMOCRIPTINE; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; LEVODOPA; NEOVASCULARIZATION, PATHOLOGIC; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SALICYLAMIDES;

EID: 70350048909     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.74     Document Type: Article

References (76)

1. Abercrombie M, Johnson ML (1946). Quantitative histology of Wallerian degeneration: I. Nuclear population in rabbit sciatic nerve. J Anat 80(Part 1): 37-50.
2. Alonso G, Galibert E, Duvoid-Guillou A, Vincent A (2005). Hyperosmotic stimulus induces reversible angiogenesis within the hypothalamic magnocellular nuclei of the adult rat: a potential role for neuronal vascular endothelial growth factor. BMC Neurosci 6: 20.
3. Astradsson A, Jenkins BG, Choi JK, Hallett PJ, Levesque MA, McDowell JS et al (2009). The blood-brain barrier is intact after levodopa induced dyskinesias in parkinsonian primatesF evidence from in vivo neuroimaging studies. Neurobiol Dis. Jun 6 (e-pub ahead of print).
4. Bacic F, Uematsu S, McCarron RM, Spatz M (1991). Dopaminergic receptors linked to adenylate cyclase in human cerebromicro-vascular endothelium. J Neurochem 57: 1774-1780.
5. Bardo MT, Valone JM, Bevins RA (1999). Locomotion and conditioned place preference produced by acute intravenous amphetamine: role of dopamine receptors and individual differences in amphetamine self-administration. Psychopharma-cology (Berl) 143: 39-46.
6. Barnum CJ, Eskow KL, Dupre K, Blandino Jr P, Deak T, Bishop C (2008). Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience 156: 30-41.
7. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O et al (2008). Decreased blood-brain barrier P-glyco-protein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 115: 1001-1009.
8. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS et al (2001). The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7: 569-574. (Pubitemid 32448324)
9. Carmeliet P (2003). Angiogenesis in health and disease. Nat Med 9(Angiogenesis focus): 653-660.
10. Cassella JP, Lawrenson JG, Allt G, Firth JA (1996). Ontogeny of four blood-brain barrier markers: an immunocytochemical comparison of pial and cerebral cortical microvessels. J Anat 189(Part 2): 407-415.
11. Cavaglia M, Dombrowski SM, Drazba J, Vasanji A, Bokesch P.M, Janigro D (2001). Regional variation in brain capillary and vascular response to ischemia. Brain Res 910: 81-93.
12. Cenci MA (2007). Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30: 236-243.
13. Cenci MA, Lee CS, Bjorklund A (1998).-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur J Neurosci 10: 2694-2706.
14. Cenci MA, Lindgren HS (2007). Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 17: 665-671.
15. Cenci MA, Lundblad M (2006). Post-vs presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99: 381-392.
16. Cenci MA, Lundblad M (2007). Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci Chapter 9, Unit 9 25.
17. Chase TN (1998). Levodopa therapy: consequences of the non-physiologic replacement of dopamine. Neurology 50(5 Suppl 5): S17-S25.
18. Choi JK, Chen YI, Hamel E, Jenkins BG (2006). Brain hemody-namic changes mediated by dopamine receptors: role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage 30: 700-712.
19. Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low MJ et al (2005). Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology 146: 2952-2962.
20. Dawson TM, Barone P, Sidhu A, Wamsley JK, Chase TN (1988). The D1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand. Neu-roscience 26: 83-100.
21. Edvinsson L, McCulloch J, Sharkey J (1985). Vasomotor responses of cerebral arterioles in situ to putative dopamine receptor agonists. Br J Pharmacol 85: 403-410.
22. Ekstrand J, Hellsten J, Tingstrom A (2008a). Environmental enrichment, exercise and corticosterone affect endothelial cell proliferation in adult rat hippocampus and prefrontal cortex. Neurosci Lett 442: 203-207.
23. Ekstrand J, Hellsten J, Wennstrom M, Tingstrom A (2008b). Differential inhibition of neurogenesis and angiogenesis by corticosterone in rats stimulated with electroconvulsive seizures. Prog Neuropsychopharmacol Biol Psychiatry 32: 1466-1472.
24. Faraci FM, Brian Jr JE (1994). Nitric oxide and the cerebral circulation. Stroke 25: 692-703.
25. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC (1999). Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353: 981-982.
26. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM (2001). Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16: 642-650.
27. Frederiksen K, McKay RD (1988). Proliferation and differentiation of rat neuroepithelial precursor cells in vivo. J Neurosci 8: 1144-1151.
28. Gallo V, Armstrong R (1995). Developmental growth factor-induced regulation of nestin in oligodendrocyte lineage cells. J Neurosc 15: 394-406.
29. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22: 5042-5054.
30. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J et al (2006). Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyper-permeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147: 5400-5411.
31. Gundersen HJ, Jensen EB (1987). The efficiency of systematic sampling in stereology and its prediction. J Microsc 147(Part 3): 229-263.
32. Hawkins BT, Brown RC, Davis TP (2002). Smoking and ischemic stroke: a role for nicotine? Trends Pharmacol Sci 23: 78-82.
33. Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V et al (2008). Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci 28: 4201-4209.
34. Ivens S, Kaufer D, Flores LP, Bechmann I, Zumsteg D, Tomkins O et al (2007). TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 130(Part 2): 535-547.
35. Kleim JA, Cooper NR, VandenBerg PM (2002). Exercise induces angiogenesis but does not alter movement representations within rat motor cortex. Brain Res 934: 1-6.
36. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT et al (2005). Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57: 176-179. (Pubitemid 40179854)
37. Kvernmo T, Hartter S, Burger E (2006). A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28: 1065-1078.
38. LaHoste GJ, Marshall JF (1990). Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists. Behav Brain Res 38: 233-242.
39. Larsen JO, Gundersen HJ, Nielsen J (1998). Global spatial sampling with isotropic virtual planes: estimators of length density and total length in thick, arbitrarily orientated sections. J Microsc 191: 238-248.
40. Lees AJ, Stern GM (1981). Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 44: 1020-1023.
41. Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA (2007). The 'motor complication syndrome' in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 177: 150-159.
42. Lu C, Pelech S, Zhang H, Bond J, Spach K, Noubade R et al (2008). Pertussis toxin induces angiogenesis in brain microvascular endothelial cells. J Neurosci Res 86: 2624-2640.
43. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002). Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15: 120-132.
44. Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M et al (2004). Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 24: 6659-6666.
45. Mokry J, Nemeneck S (1999). Cerebral angiogenesis shows nestin expression in endothelial cells. Gen Physiolo Biophys 18(Suppl 1): 25-29.
46. Monville C, Torres EM, Dunnett SB (2005). Validation of the L-Dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res Bull 68: 16-23.
47. Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA (2009). Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neuro-science 159: 927-935.
48. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press Inc: San Diego, California.
49. Pearce RK, Banerji T, Jenner P, Marsden CD (1998). De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13: 234-241.
50. Perachon S, Schwartz JC, Sokoloff P (1999). Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. Eur J Pharmacol 366: 293-300.
51. Pollack AE, Fink JS (1996). Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res 743: 124-130.
52. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D (2007). Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 62: 588-596.
53. Quik M, O'Leary K, Tanner CM (2008). Nicotine and Parkinson's disease: implications for therapy. Mov Disord 23: 1641-1652.
54. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M (1979). Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 42: 143-150.
55. Ristori C, Ferretti ME, Pavan B, Cervellati F, Casini G, Catalani E et al (2008). Adenylyl cyclase/cAMP system involvement in the antiangiogenic effect of somatostatin in the retina. Results from transgenic mice. Neurochem Res 33: 1247-1255.
56. Robertson GS, Robertson HA (1989). Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9: 3326-3331.
57. Rosenstein JM, Mani N, Silverman WF, Krum JM (1998). Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci USA 95: 7086-7091.
58. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA et al (2007). Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27: 6995-7005.
59. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S (2004). Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol 287: H1554-H1560.
60. Savasta M, Dubois A, Benavides J, Scatton B (1986a). Different neuronal location of [3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra in the rat. Neurosci Lett 72: 265-271.
61. Savasta M, Dubois A, Scatton B (1986b). Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390. Brain Res 375: 291-301.
62. Schindler CW, Carmona GN (2002). Effects of dopamine agonists and antagonists on locomotor activity in male and female rats. Pharmacol Biochem Behav 72: 857-863.
63. Schuster S, Nadjar A, Guo JT, Li Q, Ittrich C, Hengerer B et al (2008). The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci 28: 4311-4316.
64. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD et al (1977). The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897-916.
65. Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ et al (2008). Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2: CD006564.
66. Swain RA, Harris AB, Wiener EC, Dutka MV, Morris HD, Theien BE et al (2003). Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat. Neuroscience 117: 1037-1046.
67. Taylor JL, Bishop C, Walker PD (2005). Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav 81: 887-893.
68. Trugman JM, Wooten GF (1986). The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra. Brain Res 379: 264-274.
69. Trugman JM, Wooten GF (1987). Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions. J Neurosci 7: 2927-2935.
70. van Vliet EA, da Costa Araujo S, Redeker S, van Schaik R, Aronica E, Gorter JA (2007). Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130(Part 2): 521-534.
71. Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P et al (2006). Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L- alanine-induced dyskinesia. J Neurosci 26: 9448-9461.
72. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007). Spatiotemporal pattern of striatal ERK1/2 phosphory-lation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62: 800-810.
73. Yasuda T, Fukuda-Tani M, Nihira T, Wada K, Hattori N, Mizuno Y et al (2007). Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease. Exp Neurol 206: 308-317.
74. Zacchigna S, Lambrechts D, Carmeliet P (2008). Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 9: 169-181.
75. Zachary I, Gliki G (2001). Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 49: 568-581. (Pubitemid 32146420)
76. Zou AP, Cowley Jr AW (2000). Alpha(2)-adrenergic receptor-mediated increase in NO production buffers renal medullary vasoconstriction. Am J Physiol Regul Integr Comp Physiol 279: R769-R777.